Biotechnology

WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors

SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 "Most Honored Companies" in new rankings from Extel ...

2025-06-16 20:00 2037

PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL

HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...

2025-06-16 19:00 1677

NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease

Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease * Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed h...

2025-06-16 19:00 1956

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

* Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg * The FDA previously approved STEQEYMA® 45mg/0.5mL, 90mg/mL in a single-dose prefilled syrin...

2025-06-16 07:30 2004

Samsung Biologics launches drug screening services, Samsung Organoids

* Samsung Organoids to provide data-driven analysis of candidate molecules * Samsung Biologics expands service scope to include preclinical research INCHEON,South Korea, June 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organizat...

2025-06-16 07:30 2144

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

* Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatments * To accelerate partnering efforts with global pharmaceutical companies and potential clients, while exploring business collaborations in imaging CRO sec...

2025-06-13 21:00 2539

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof.Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) ha...

2025-06-13 17:02 1544

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2025-06-13 09:00 2250

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to la...

2025-06-13 00:01 2180

Turning Partnerships into Global Healthcare Solutions with VARON Oxygen Solutions

NEW YORK, June 12, 2025 /PRNewswire/ -- In hospitals, senior living centers, and clinics around the globe, lives are being improved every day by a quiet but powerful force in respiratory care: VARON Oxygen Solutions. Known for its high-quality o...

2025-06-12 20:50 1518

Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated ...

2025-06-12 20:03 1882

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% * DZD8586 exhibited significant antitumor activity in heavily pretreated chronic l...

2025-06-12 18:13 1853

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025

BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking placeJune 16-19 in Boston Convention & Exhibition Cen...

2025-06-12 15:39 1850

Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025

TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking placeJune 16–19 in Boston, MA. The c...

2025-06-11 15:58 1958

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- ...

2025-06-11 12:00 2390

Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation

CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine , a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the recent release of its Nach01 foundation model on Amazon Web Services (AWS), available via AWS...

2025-06-10 21:00 2463

ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

SUZHOU, China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatment of cancer, announced that the first patient diagnosed with NMIBC has been dosed in a multi-regiona...

2025-06-10 20:00 2369

Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates

SHANGHAI and NEW YORK, June 10, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leadingShanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., aNew York-based biotechnology company...

2025-06-10 18:00 2521

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

* LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals inthe United States and Europe, who progress rapidly to end-stage heart failure. * NVC-001 demonstrated significant benefits, including survival and cardiac ...

2025-06-10 16:49 1647

Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025

* Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. * For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined withGLP-1 ...

2025-06-10 16:15 1901
1 ... 23242526272829 ... 159